Moors & Cabot’s Organogenesis Holdings ORGO Stock Holding History

Moors & Cabot’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-66,350	Closed	-$211K	–	882
2023 Q3	$211K	Hold	66,350	–	–	0.01%	731
2023 Q2	$220K	Hold	66,350	–	–	0.01%	715
2023 Q1	$141K	Hold	66,350	–	–	0.01%	787
2022 Q4	$178K	Hold	66,350	–	–	0.01%	757
2022 Q3	$215K	Hold	66,350	–	–	0.02%	679
2022 Q2	$324K	Hold	66,350	–	–	0.02%	534
2022 Q1	$506K	Hold	66,350	–	–	0.03%	465
2021 Q4	$613K	Hold	66,350	–	–	0.04%	403
2021 Q3	$945K	Hold	66,350	–	–	0.06%	293
2021 Q2	$1.1M	Sell	66,350 -25,000	-27%	-$466K	0.08%	248
2021 Q1	$1.66M	Hold	91,350	–	–	0.13%	162
2020 Q4	$688K	Hold	91,350	–	–	0.06%	288
2020 Q3	$351K	Hold	91,350	–	–	0.03%	430
2020 Q2	$351K	Hold	91,350	–	–	0.04%	401
2020 Q1	$295K	Hold	91,350	–	–	0.04%	378
2019 Q4	$439K	Hold	91,350	–	–	0.04%	371
2019 Q3	$600K	Hold	91,350	–	–	0.07%	281
2019 Q2	$694K	Buy	+91,350	New	+$672K	0.09%	239

Other funds holding ORGO

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Moors & Cabot's ORGO Position: Q4 2023 in Review

Moors & Cabot sold out of Organogenesis Holdings (ORGO) in Q4 2023, closing a stake of 66,350 shares — an estimated $211K sold.

Moors & Cabot first reported a position in ORGO in Q2 2019 and held it in 18 quarters. The position peaked at $1.66M in Q1 2021. 108 funds tracked by Wall St. Rank hold ORGO as of Q4 2023.

Moors & Cabot reported no remaining Organogenesis Holdings position as of Q4 2023 after selling out during the quarter.
Moors & Cabot sold 66,350 Organogenesis Holdings shares in Q4 2023, an estimated $211K.
Moors & Cabot first reported a position in Organogenesis Holdings in Q2 2019 and held it in 18 quarters.
Moors & Cabot's Organogenesis Holdings position peaked at $1.66M in Q1 2021.
108 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q4 2023.

Based on Moors & Cabot's 13F filing for Q4 2023, filed 14 Feb 2024.